<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055237</url>
  </required_header>
  <id_info>
    <org_study_id>030110</org_study_id>
    <secondary_id>03-C-0110</secondary_id>
    <nct_id>NCT00055237</nct_id>
    <nct_alias>NCT00058136</nct_alias>
  </id_info>
  <brief_title>Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients</brief_title>
  <official_title>Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and effectiveness of the experimental drug bevacizumab for&#xD;
      treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated Kaposi's&#xD;
      sarcoma (KS). KS tumors depend on the formation of new blood vessels for their growth.&#xD;
      Bevacizumab is an antibody to a protein called vascular endothelial growth factor (VEGF) that&#xD;
      is produced by the body and is involved in blood vessel growth. Bevacizumab may block the&#xD;
      action of VEGF, and thus help shrink KS lesions.&#xD;
&#xD;
      Patients 18 years of age and older with Kaposi's sarcoma that is restricted to the skin and&#xD;
      is not life threatening may be eligible for this study. Candidates will be screened with a&#xD;
      medical history and physical examination, blood and urine tests, electrocardiogram (EKG),&#xD;
      chest x-ray, and, if needed, imaging studies to evaluate internal tumors.&#xD;
&#xD;
      Participants will receive bevacizumab intravenously (by vein) once a week for 2 weeks and&#xD;
      then every 3 weeks at the National Institutes of Health (NIH) Clinical Center. The first&#xD;
      infusion takes about 90 minutes, the second takes about 60 minutes, and subsequent infusions&#xD;
      take about 30 minutes. Infusions may take longer, however, if the drug is better tolerated at&#xD;
      a slower infusion rate. Patients will be evaluated with the following tests and procedures:&#xD;
&#xD;
        -  Physical examination, assessment of drug side effects, measurement of KS lesions, and&#xD;
           photographs of lesions once a week for the first 6 weeks of therapy, and then every 3&#xD;
           weeks.&#xD;
&#xD;
        -  cluster of differentiation 4 (CD4) cell counts and human immunodeficiency virus (HIV)&#xD;
           viral load in HIV-positive patients every 12 weeks.&#xD;
&#xD;
        -  Biopsies of lesions: upon entering the study, at week 12, and at the time of a response&#xD;
           of the tumor to therapy or at the end of treatment, if treatment ends at week 18 or&#xD;
           later.&#xD;
&#xD;
        -  Additional biopsies, if requested. (Additional biopsies are not required.)&#xD;
&#xD;
        -  Other procedures, such as computed tomography (CT) or magnetic resonance imaging (MRI)&#xD;
           scans, if medically indicated.&#xD;
&#xD;
      Patients may continue bevacizumab therapy indefinitely if they are benefiting from it, as&#xD;
      long as they have no substantial toxicity or other conditions that would cause them to stop&#xD;
      receiving it and the protocol remains open.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:&#xD;
&#xD;
      This is a phase II study to determine the activity of bevacizumab, a putative antiangiogenic&#xD;
      agent, in Kaposi's sarcoma (KS). Bevacizumab is a humanized recombinant antibody to vascular&#xD;
      endothelial cell growth factor (VEGF), an important cytokine in the pathogenesis of KS.&#xD;
&#xD;
      OBJECTIVES:&#xD;
&#xD;
      To assess the antitumor effect of bevacizumab 15 mg/kg administered intravenously once every&#xD;
      three weeks in patients with human immunodeficiency virus (HIV)-associated Kaposi's sarcoma&#xD;
      (KS). Other objectives include assessment of the antitumor effect of bevacizumab 15 mg/kg&#xD;
      administered intravenously once every three weeks in patients with classical KS; assessment&#xD;
      of the toxicity profile of bevacizumab in HIV-infected and HIV-negative patients with KS;&#xD;
      exploration in a preliminary fashion effect of bevacizumab on KS progression free survival;&#xD;
      and study of a number of biochemical parameters, including stromal cell-derived factor-1&#xD;
      (SDF-1) expression in KS lesions; human herpes virus-8 (HHV-8) viral load in peripheral blood&#xD;
      mononuclear cells; serum vascular endothelial growth factor (VEGF) levels over the course of&#xD;
      treatment; and changes in viral interleukin 6 (IL-6) levels over the course of treatment.&#xD;
&#xD;
      ELIGIBILITY:&#xD;
&#xD;
      Key eligibility parameters include HIV-associated or classical Kaposi's sarcoma, age greater&#xD;
      than or equal to 18 years, and life expectancy greater than 6 months. Patients with HIV&#xD;
      infection must have either KS progression on a regimen of highly active antiretroviral&#xD;
      therapy (HAART) for at least one month, or no KS regression while on an optimized regimen of&#xD;
      HAART for 4 months or longer.&#xD;
&#xD;
      DESIGN:&#xD;
&#xD;
      Patients will be sequentially enrolled, administered a loading dose of 15 mg/kg bevacizumab&#xD;
      intravenously on day 1, and then administered 15 mg/kg bevacizumab intravenously every 3&#xD;
      weeks beginning one week after the loading dose. The drug will be temporarily discontinued&#xD;
      for toxicity, intercurrent major surgical procedures, or other factors that would pose a&#xD;
      safety concern. Patients will undergo a biopsy of a KS lesion at entry, on cycle 4, day 21,&#xD;
      and at the time of a formal response or when the patient stops treatment. Patients will&#xD;
      undergo a number of other tests as well, including blood tests and non-invasive imaging&#xD;
      studies of KS lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2003</start_date>
  <completion_date type="Actual">March 15, 2010</completion_date>
  <primary_completion_date type="Actual">March 15, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>Percentage of participants with a complete response (CR) + partial response (PR)per the Modified AIDS Clinical Trial Group Criteria (ACTG) for HIV-KS. PR is a 50% decrease in the number and/or size of previously existing lesions for 4 weeks; or complete flattening of at least 50% of all previously raised lesions lasting for at least 4 weeks; or a 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions lasting for at least 4 weeks; CR is the absence of any detectable residual disease, including tumor associated edema, persisting for at least 4 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>70 months</time_frame>
    <description>Here are the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Kaposi's Sarcoma</condition>
  <condition>HIV Infections</condition>
  <condition>HIV Seronegativity</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Pts with HIV-associated Kaposi's Sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.</description>
    <arm_group_label>Cohort 1: Pts with HIV-associated Kaposi's Sarcoma</arm_group_label>
    <arm_group_label>Cohort 2: Pts with classic Kaposi's Sarcoma (HIV-uninfected)</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Age greater than or equal to 18 years.&#xD;
&#xD;
        Kaposi's sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology.&#xD;
&#xD;
        Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.&#xD;
&#xD;
        Life expectancy greater than 6 months.&#xD;
&#xD;
        The following hematologic parameters:&#xD;
&#xD;
          -  Hemoglobin greater than 9 g/dl;&#xD;
&#xD;
          -  White blood cell (WBC) greater than 1000/mm^3;&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) greater than 750/mm^3;&#xD;
&#xD;
          -  Platelets greater than 75,000/mm^3;&#xD;
&#xD;
          -  Prothrombin time (PT) and partial thromboplastin time (PTT) less than or equal to 120%&#xD;
             of control, unless patient has the presence of a lupus anticoagulant.&#xD;
&#xD;
        The following hepatic parameters:&#xD;
&#xD;
        Bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) unless the&#xD;
        patient is receiving protease inhibitor therapy known to be associated with increased&#xD;
        bilirubin:&#xD;
&#xD;
        in this case total bilirubin less than or equal to 7.5 mg/dl and the direct fraction less&#xD;
        than or equal to 0.7 mg/dl.&#xD;
&#xD;
        -Examples of protease inhibitors known to increase bilirubin levels include indinavir,&#xD;
        ritonavir, nelfinavir, and atazanavir.&#xD;
&#xD;
        Aspartate aminotransferase (AST)/glutamic oxaloacetic transaminase (GOT) less than or equal&#xD;
        to 2.5 times the upper limit of normal.&#xD;
&#xD;
        Either Serum creatinine less than or equal to 1.5 mg/dL or measured creatinine clearance&#xD;
        greater than or equal to 60 mL/min.&#xD;
&#xD;
        Either Urine protein less than 1+ or measured 24 hour urine protein less than 500&#xD;
        milligram.&#xD;
&#xD;
        Blood pressure: systolic blood pressure (SBP) less than 160 mm/Hg; diastolic blood pressure&#xD;
        (DBP) less than 95 mm/Hg.&#xD;
&#xD;
        At least 5 assessable cutaneous lesions previously untreated by local therapy.&#xD;
&#xD;
        Patients with human immunodeficiency virus (HIV) infection must be willing to comply with a&#xD;
        regimen of highly active antiretroviral therapy and be on a regimen of highly active&#xD;
        antiretroviral therapy (HAART) selected for best potential efficacy for at least 1 month&#xD;
        with evidence of Kaposi sarcoma (KS) progression on the HAART regimen or be on a optimized&#xD;
        regimen of HAART for 4 months or longer with no evidence of KS regression.&#xD;
&#xD;
        Patients must be willing to use effective birth control.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Symptomatic, extensive pulmonary involvement.&#xD;
&#xD;
        Symptomatic visceral KS excluding the oral cavity.&#xD;
&#xD;
        Inability to provide informed consent.&#xD;
&#xD;
        Chemotherapy within 3 weeks.&#xD;
&#xD;
        Prior therapy with SU5416.&#xD;
&#xD;
        Supraphysiologic doses of corticosteroids within 3 weeks.&#xD;
&#xD;
        Major surgical procedure (including periodontal) within 4 weeks.&#xD;
&#xD;
        Surgical or other non-healing wounds unrelated to KS.&#xD;
&#xD;
        Pregnancy.&#xD;
&#xD;
        Breast feeding.&#xD;
&#xD;
        Past or present history of malignant tumors other than KS unless: a) in a complete&#xD;
        remission for greater than or equal to 1 year from the time a response was first&#xD;
        documented; b) completely resected basal cell carcinoma; or c) in situ squamous cell&#xD;
        carcinoma of the cervix or anus.&#xD;
&#xD;
        Evidence of a severe or life-threatening infection within 2 weeks of entry onto the study.&#xD;
&#xD;
        A condition that would require the patient to receive intravenous antibiotics on a day of&#xD;
        bevacizumab infusion.&#xD;
&#xD;
        Need for chronic daily aspirin greater than or equal to 325 mg/daily or nonsteroidal&#xD;
        medication interfering with platelet function.&#xD;
&#xD;
        Therapeutic anticoagulation with international normalized ratio (INR) greater than 1.5,&#xD;
        unless the patient is on full dose warfarin. If a patient is on full-dose anticoagulants,&#xD;
        the following criteria should be met for enrollment:&#xD;
&#xD;
        The subject must have an in-range INR (usually between 2 and 3) on a stable dose of&#xD;
        warfarin or on stable dose of low molecular weight (LMW) heparin;&#xD;
&#xD;
        The subject must not have active bleeding or pathological conditions that carry high risk&#xD;
        of bleeding (e.g. tumor involving major vessels).&#xD;
&#xD;
        History of deep venous or arterial thrombosis.&#xD;
&#xD;
        History of gastrointestinal bleeding.&#xD;
&#xD;
        Clinically significant cardiovascular disease such as uncontrolled hypertension (with&#xD;
        systolic BP greater than 160 mm/Hg or diastolic blood pressure greater than 95 mm/Hg),&#xD;
        unstable angina, New York Heart Association grade II or greater congestive heart failure,&#xD;
        cardiac arrhythmia requiring medication, clinically significant peripheral artery disease,&#xD;
        grade II or greater peripheral vascular disease, myocardial infarction.&#xD;
&#xD;
        Substantial central nervous system (CNS) disease including history of CNS bleeding, mass&#xD;
        lesions in the brain, uncontrolled seizure disorder, recent history of cerebrovascular&#xD;
        accident (CVA) (e.g. within the past 6 months), history of transient ischemic attack (TIA)&#xD;
        within the past 6 months..&#xD;
&#xD;
        Coagulopathy.&#xD;
&#xD;
        Patients with unstable bone fractures that are not stress/weight bearing able.&#xD;
&#xD;
        Patients with any other abnormality that would be scored as a grade 3 toxicity, except&#xD;
        lymphopenia, direct manifestations of KS, direct manifestation of HIV, direct manifestation&#xD;
        of HIV therapy, hyperbilirubinemia associated with protease inhibitors, asymptomatic&#xD;
        hyperuricemia.&#xD;
&#xD;
        Previous intravenous immunoglobulin (IVIG) or monoclonal antibody therapy within 30 days&#xD;
        prior to enrollment.&#xD;
&#xD;
        Known hypersensitivity to bevacizumab.&#xD;
&#xD;
        Known hypersensitivity to Chinese hamster ovary cell products.&#xD;
&#xD;
        Known hypersensitivity to other recombinant human or humanized antibodies.&#xD;
&#xD;
        Previous bevacizumab.&#xD;
&#xD;
        Any condition that, in the opinion of the Principal Investigator or Study Chairperson,&#xD;
        would preclude the inclusion of a patient onto this research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Yarchoan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute, National Institutes of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Uldrick TS, Wyvill KM, Kumar P, O'Mahony D, Bernstein W, Aleman K, Polizzotto MN, Steinberg SM, Pittaluga S, Marshall V, Whitby D, Little RF, Yarchoan R. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol. 2012 May 1;30(13):1476-83. doi: 10.1200/JCO.2011.39.6853. Epub 2012 Mar 19.</citation>
    <PMID>22430271</PMID>
  </results_reference>
  <results_reference>
    <citation>Uldrick T, Wyvill K, Kumar P, Bernstein W, O'Mahony D, Polizzotto M, Aleman K, Steinberg S, Pittaluga S, Little R, and Yarchoan R. A Phase II Study Targeting Vascular Endothelial Growth Factor with the Humanized Monoclonal Antibody Bevacizumab in the Treatment of Patients with HIV-Associated Kaposi Sarcoma. 17th Conference on Retroviruses and Opportunistic Infections. Oral Presentation. February 17, 2010.</citation>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>February 21, 2003</study_first_submitted>
  <study_first_submitted_qc>February 20, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2003</study_first_posted>
  <results_first_submitted>June 19, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2012</results_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Robert Yarchoan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Angiogenesis</keyword>
  <keyword>Cancer</keyword>
  <keyword>HHV-8</keyword>
  <keyword>KSHV</keyword>
  <keyword>Skin</keyword>
  <keyword>Kaposi Sarcoma</keyword>
  <keyword>KS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma</title>
          <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected)</title>
          <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma</title>
          <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Pts With Classic Kaposi's Sarcoma (HIV-uninfected)</title>
          <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="9.3"/>
                    <measurement group_id="B2" value="58" spread="12.7"/>
                    <measurement group_id="B3" value="50" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate</title>
        <description>Percentage of participants with a complete response (CR) + partial response (PR)per the Modified AIDS Clinical Trial Group Criteria (ACTG) for HIV-KS. PR is a 50% decrease in the number and/or size of previously existing lesions for 4 weeks; or complete flattening of at least 50% of all previously raised lesions lasting for at least 4 weeks; or a 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions lasting for at least 4 weeks; CR is the absence of any detectable residual disease, including tumor associated edema, persisting for at least 4 weeks.</description>
        <time_frame>36 months</time_frame>
        <population>Cohort 2 is not reported here because response rate in HIV negative patients was a secondary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Cohort 1: Pts With HIV-associated Kaposi's Sarcoma</title>
            <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Percentage of participants with a complete response (CR) + partial response (PR)per the Modified AIDS Clinical Trial Group Criteria (ACTG) for HIV-KS. PR is a 50% decrease in the number and/or size of previously existing lesions for 4 weeks; or complete flattening of at least 50% of all previously raised lesions lasting for at least 4 weeks; or a 50% decrease in the sum of the products of the largest perpendicular diameters of the marker lesions lasting for at least 4 weeks; CR is the absence of any detectable residual disease, including tumor associated edema, persisting for at least 4 weeks.</description>
          <population>Cohort 2 is not reported here because response rate in HIV negative patients was a secondary outcome.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="11" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>proportion estimate,binomial exact 95%CI</param_type>
            <param_value>31</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>11.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11</ci_lower_limit>
            <ci_upper_limit>58.7</ci_upper_limit>
            <estimate_desc>As stated in the Outcome statistical Analysis 1. Section, the confidence interval was calculated using binomial exact statistics. The standard deviation is based on that calculation.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here are the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module.</description>
        <time_frame>70 months</time_frame>
        <population>All adverse events regardless of attribution, over 202 cycles in 19 patients. Per protocol analysis of adverse events.&#xD;
Cohort 1 and 2 are reported together.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 &amp; 2: Pts With HIV-associated and Classic KS</title>
            <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Here are the number of participants with adverse events. For the detailed list of adverse events, see the adverse event module.</description>
          <population>All adverse events regardless of attribution, over 202 cycles in 19 patients. Per protocol analysis of adverse events.&#xD;
Cohort 1 and 2 are reported together.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>70 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 &amp; 2: Pts With HIV-associated and Classic KS</title>
          <description>15 mg/kg bevacizumab intravenously on days 1 and 8 then every 3 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Transfusion: Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Syndromes-Other (Specify, toxic shock syndrome)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>(documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC &lt;1.0 x 10e</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection/Febrile Neutropenia-Other (Specify, from leg cellulitis)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bicarbonate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis (metabolic or respiratory)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv2.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis (e.g., immune hemolytic anemia, drug related hemolysis, other)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemorrhage-Other (Specify, gums; gums bleeding)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="25" subjects_affected="11" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac left ventricular function</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I (cTnI)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/Hearing-Other (Specify, hearing loss)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vision-blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vision-flashing lights/floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (Specify, bloating fullness; slight indigestion)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Mouth dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rectal bleeding/hematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>(in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</description>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pain-Other (back pain;leg pain; heel pain; throat pain; from leg cellulitis; in R posterior knee)</sub_title>
                <description>continued plantar fascilitis;jaw pain;knee pain;local pain foot/leg;pressure R mid back;sore throat;tooth pain;burn L thumb;chest pain;cramps in feet;soreness L index finger;knee-tumor pain;leg pain;side mandibular LN tender; infection,abcess tooth</description>
                <counts group_id="E1" events="27" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rigors, chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Infection/Febrile Neutropenia-Other (Specify)</sub_title>
                <description>fungal infections, feet tinea pedis; URI; swelling behind R knee; tinea L axilla</description>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Amylase</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="26" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>CPK (creatine phosphokinase)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="31" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="33" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>for leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Partial thromboplastin time (PTT)</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Prothrombin time (PT)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>SGOT (AST) (serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="45" subjects_affected="13" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" events="22" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>CD4 count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <description>Neutrophils/granulocytes (ANC/AGC) for leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.</description>
                <counts group_id="E1" events="54" subjects_affected="13" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="13" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal-Other (Specify, joint stiffness)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Arthralgia (joint pain)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain (onset or exacerbation of tumor pain due to treatment)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="30" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neuropathy - cranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria (painful urination)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hematuria (in the absence of vaginal bleeding)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="23" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="56" subjects_affected="14" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="15" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other (Specify, sneezing)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify, foot callous; burning sensation in abdominal area)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pigmentation changes (e.g., vitiligo)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sweating (diaphoresis)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Phlebitis (superficial)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Yarchoan, M.D.</name_or_title>
      <organization>National Cancer Institute, National Institutes of Health</organization>
      <phone>301-496-0328</phone>
      <email>Robert.Yarchoan@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

